Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello! Hope you had a restful and reflective long weekend. Today, we talk a lot about regulatory policy — for flu vaccines and for physicians. We also speak with the new NIH director about how she’s finding a balance between government and industry priorities, and explore the feared brain drain from the new, $500 million research initiative that just launched in Kendall Square.
The new NIH director’s balancing act
Monica Bertagnolli, the new director of the NIH, is torn between President Biden’s drug pricing agenda and the priorities of the broader biopharmaceutical industry. Biden’s stance is simple: “You shouldn’t pay the highest price in the world for drugs that your tax dollars have already helped create,” he said last month.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect